TWP
DCPH

TFO Wealth Partners’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

TFO Wealth Partners’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed -$795 – 933
2022
Q4 		$795 Buy
+30
New +$488 ﹤0.01% 405

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TFO Wealth Partners's DCPH Position: Q1 2023 in Review

TFO Wealth Partners sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2023, closing a stake of 30 shares — an estimated $795 sold.

TFO Wealth Partners first reported a position in DCPH in Q4 2022 and held it in 1 quarter. The position peaked at $795 in Q4 2022. 146 funds tracked by Wall St. Rank hold DCPH as of Q1 2023.

  • TFO Wealth Partners reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • TFO Wealth Partners sold 30 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $795.
  • TFO Wealth Partners first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • TFO Wealth Partners's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $795 in Q4 2022.
  • 146 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on TFO Wealth Partners's 13F filing for Q1 2023, filed 3 May 2023.